| IV-01 Khaled Abduljalil Application of Physiologically-Based Pharmacokinetic model To Predict Tramadol Concentration in human Milk Thursday 14:45-16:15 |
| IV-02 João Abrantes Handling inter-occasion variability in model-based therapeutic drug monitoring Thursday 14:45-16:15 |
| IV-03 Malidi Ahamadi Operating Characteristics of Stepwise Covariate Selection in Pharmacometric Modeling Thursday 14:45-16:15 |
| IV-04 Pascal André Population pharmacokinetics of vancomycin delivered from active calcium sulfate bone graft substitute. Thursday 14:45-16:15 |
| IV-05 Louise Andrews New population pharmacokinetic model that predicts the individual starting dose of tacrolimus following pediatric renal transplantation Thursday 14:45-16:15 |
| IV-06 Usman Arshad Population pharmacokinetic model of mitotane enzyme autoinduction in adrenocortical carcinoma patients Thursday 14:45-16:15 |
| IV-07 Muhammad Waqar Ashraf A semi-mechanistic model to characterize the pharmacokinetics of orally administered S-Ketamine in healthy human subjects Thursday 14:45-16:15 |
| IV-08 Eduardo Asín-Prieto An Immune quantitative network aimed for viral hepatitis B Thursday 14:45-16:15 |
| IV-09 Geraldine Celliere Target-mediated drug-disposition (TMDD) model comparison using the MonolixSuite Thursday 14:45-16:15 |
| IV-10 Hyun-moon Back Development of a Semi-mechanistic absorption model for explaining effect of food on itraconazole Thursday 14:45-16:15 |
| IV-11 Suruchi Bakshi Systems pharmacology modelling of alternative pathway of complement activation Thursday 14:45-16:15 |
| IV-12 Pavel Balazki Physiologically-based Pharmacokinetics/Pharmacodynamics model of Dapagliflozin, an oral SGLT2 inhibitor Thursday 14:45-16:15 |
| IV-13 Violeta Balbas-Martinez Validation of a Network Systems Pharmacology model for Inflammatory Bowel Thursday 14:45-16:15 |
| IV-14 Guillaume Baneyx Population pharmacokinetic modeling of pazopanib in healthy volunteers and patients with advanced renal cell carcinoma. Thursday 14:45-16:15 |
| IV-15 Catalina Barceló Modelling body mass index trajectory in HIV-infected individuals Thursday 14:45-16:15 |
| IV-16 Carla Bastida Fernández Population pharmacokinetic model for intravenous tocilizumab in rheumatoid arthritis Thursday 14:45-16:15 |
| IV-17 Brendan Bender A Mechanism-Based Model of Tumor Quiescence and Resistance in HER2-Negative Metastatic Breast Cancer in Patients Receiving Docetaxel or Paclitaxel Thursday 14:45-16:15 |
| IV-18 Sophie Berends A Target-Mediated Drug Disposition model for infliximab in patients with Ulcerative Colitis Thursday 14:45-16:15 |
| IV-19 Aliénor Bergès Dose-exposure-response model between an ATR inhibitor and peripheral monocytes Thursday 14:45-16:15 |
| IV-20 Julie Bertrand Joint pharmacogenetic model of tenofovir and emtricitabine and their active intracellular metabolites in HIV Patients Thursday 14:45-16:15 |
| IV-21 Souvik Bhattacharya Longitudinal Parkinson’s Disease Progression Model using Item-Response-Theory Utilized to Predict Treatment Effect of Levodopa Thursday 14:45-16:15 |
| IV-22 Bruno Bieth Use of population PK/PD modeling to support the regulatory approval of canakinumab as first biologic treatment in patients with periodic fever syndromes Thursday 14:45-16:15 |
| IV-23 Roberto Bizzotto A model of insulin kinetics describing tests with various insulin secretion and infusion patterns by means of a consistent mechanism Thursday 14:45-16:15 |
| IV-24 Agnieszka Borsuk-De Moor Tigecycline population pharmacokinetics in patients with severe sepsis or septic shock resulting from abdominal surgery Thursday 14:45-16:15 |
| IV-25 Thomas Bouillon Efficient identification of the optimal dosing regimen with a nonparametric method Thursday 14:45-16:15 |
| IV-26 Ari Brekkan Viggosson Parameter Estimation in Bivariate Mixed Hidden Markov Models Thursday 14:45-16:15 |
| IV-27 Jantine Brussee Distinguishing between first-pass and systemic CYP3A-mediated metabolism of midazolam in preterm neonates using physiologically-based pharmacokinetic modelling Thursday 14:45-16:15 |
| IV-28 Núria Buil Bruna Predicting myelosuppression from phase I data: Which model should we use? Thursday 14:45-16:15 |
| IV-29 Charles Burdet Joint modeling of moxifloxacin pharmacokinetics and fecal microbiota disruption in healthy volunteers Thursday 14:45-16:15 |
| IV-30 Unai Caballero Pharmacokinetic/pharmacodynamic modeling of anidulafungin time-kill curves against Candida considering antifungal resistance Thursday 14:45-16:15 |
| IV-31 Sophie Callies Increase in glucose as pharmacodynamic biomarker following administration of the PI3K/mTOR inhibitor LY3023414: quantitative description using modelling. Thursday 14:45-16:15 |
| IV-32 Elisa Calvier Accuracy of plasma clearance scaling from adults to children using pathway-specific covariate models: a systematic investigation using a physiologically-based pharmacokinetic workflow Thursday 14:45-16:15 |
| IV-33 Letizia Carrara Which data are necessary to build a WB-PBPK model that accurately predicts exposure in the lung? A case study using Ethambutol for tuberculosis treatment Thursday 14:45-16:15 |
| IV-34 Massimo Cella CHF5993 a triple combination therapy for COPD patients: population PK modelling of glycopyrronium bromide (GB) following pMDI inhalation. Thursday 14:45-16:15 |
| IV-35 Marc Cerou Development and performance of npde for the evaluation of time-to-event model Thursday 14:45-16:15 |
| IV-36 Anne Chain An Extrapolation Approach to Aprepitant Pediatric Drug Development Thursday 14:45-16:15 |
| IV-37 Kaelig Chatel Tobramycin dose individualization using the MonolixSuite Thursday 14:45-16:15 |
| IV-38 Jonathan Chauvin Longitudinal Model-Based Meta-Analysis (MBMA) for rheumatoid arthritis with Monolix Thursday 14:45-16:15 |
| IV-39 Chao Chen A clinical trial simulation study to investigate and compare efficacy and toxicity findings in parallel and titration designs Thursday 14:45-16:15 |
| IV-40 Dina Chernikova Inhibition of bile acids synthesis via fibroblast growth factor 19 (FGF19) through intestinal signaling: A population analysis Thursday 14:45-16:15 |
| IV-41 Manoranjenni Chetty Prediction of the pharmacokinetics of renally excreted antiretrovirals in older patients, using physiologically based pharmacokinetic (PBPK) modelling. Thursday 14:45-16:15 |
| IV-42 S. Y. Amy Cheung Optimising Phase 1 oncology dosing schedule of an ATR inhibitor in real time using a model informed approach to predict myelosuppression Thursday 14:45-16:15 |
| IV-43 Maxwell Chirehwa A semi-physiological model for moxifloxacin pharmacokinetics which includes the effect of co-administered drugs and genetic polymorphisms Thursday 14:45-16:15 |
| IV-44 Joannellyn Chiu Pre-clinical Population PK Model of CF-301 - a Novel Antibacterial Lysin Thursday 14:45-16:15 |
| IV-45 Palang Chotsiri Population pharmacokinetic and time-to-event modelling of the antimalarial drug lumefantrine in young children with severe acute malnutrition Thursday 14:45-16:15 |
| IV-46 Shafi Chowdhury Using “Big” NONMEM Dataset Generated from Standard SDTM to Review Data and Accelerate Model Building Process Thursday 14:45-16:15 |
| IV-47 Pieter Colin Dexmedetomidine pharmacodynamics in healthy volunteers: Striking a balance between the hypnotic and sedative properties and the haemodynamic side effects. Thursday 14:45-16:15 |
| IV-48 Camille Couffignal Population pharmacokinetic modelling of sustained-release lithium in the serum, erythrocytes and urine of patients with bipolar disorder. Thursday 14:45-16:15 |
| IV-49 Sinziana Cristea The impact of renal transporters on paediatric renal clearance Thursday 14:45-16:15 |
| IV-50 Vincent Croixmarie DDMoRe private repository linked with an in-house PK database Thursday 14:45-16:15 |
| IV-51 André Dallmann Physiologically-based pharmacokinetic modeling of drugs metabolized via several CYP enzymes in populations of pregnant women Thursday 14:45-16:15 |
| IV-52 Olivier David CNP520 Phase III dose selection support: Identifying the doses producing a desired reduction in CSF Aß-40 Thursday 14:45-16:15 |
| IV-53 Miné De Kock Population Pharmacokinetics of Sulfadoxine and Pyrimethamine: A pooled analysis to Inform Optimal Dosing in African Children with Uncomplicated Malaria. Thursday 14:45-16:15 |
| IV-54 Mailys De Sousa Mendes Predicting human foetal exposure using physiologically based pharmacokinetic models Thursday 14:45-16:15 |
| IV-55 Aurelia de Vries Schultink Modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens. Thursday 14:45-16:15 |
| IV-56 Neel Deferm Modeling of telmisartan disposition in sandwich-cultured rat hepatocytes. Does cryopreservation change disposition kinetics? Thursday 14:45-16:15 |
| IV-57 Douglas J. Eleveld How many bits of information did my study provide? Examining Kullback-Leibler divergence, standard errors and shrinkage Thursday 14:45-16:15 |
| IV-58 Chenhui Deng Tofacitinib exposure-response modeling of partial Mayo score in ulcerative colitis patients in phase 3 induction studies Thursday 14:45-16:15 |
| IV-59 Menshykau Denis Computational Modelling of Personalized Hemodynamic Response to Valve Replacement Surgery in Heart Failure Patients Thursday 14:45-16:15 |
| IV-60 Paolo Denti Lopinavir/Ritonavir Super-boosting Overcomes Interactions In Children Treated With Rifampicin: A Model-Based Approach For Non-Inferiority Trials Thursday 14:45-16:15 |
| IV-61 Solène Desmée Mechanistic joint modelling for longitudinal PSA and survival data in advanced metastatic prostate cancer Thursday 14:45-16:15 |
| IV-62 Cheikh Diack A model-based meta-marker to characterize the response to ranibizumab in wet AMD patients Thursday 14:45-16:15 |
| IV-63 Christian Diedrich Towards population physiology based pharmacokinetics modelling (popPBPK) in an industrial environment Thursday 14:45-16:15 |
| IV-64 Richard Dimelow Effect of dataset characteristics on estimation method performance: a TMDD model example Thursday 14:45-16:15 |
| IV-65 Christiane Dings Mathematical modeling of glucose, insulin and c-peptide during the OGTT in pre-diabetic subjects: A DIRECT study Thursday 14:45-16:15 |
| IV-66 Mike Dunlavey Use of distributed delay in PML Thursday 14:45-16:15 |
| IV-67 Sulav Duwal Multiscale, mechanistic pipeline to assess the prophylactic efficacy of anti- HIV compounds Thursday 14:45-16:15 |
| IV-68 Lisa Ehmann Is a pooled population pharmacokinetic model predictive of plasma and microdialysate pharmacokinetics of linezolid in obese and non-obese patients? Thursday 14:45-16:15 |
